6 terminated. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
| Phase 2 | 2 | Terminated 2 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations Brimonidine 0.33% gel - Capillary Malformations | Phase 3 | Terminated | The Hospital for Sick Children | 6 | 2016-06-01 | 2019-04-16 |
| Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa SD-101-6.0 cream - Epidermolysis Bullosa | Phase 3 | Terminated | Scioderm, Inc. | 152 | 2015-06-09 | 2019-09-27 |
| A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing ABH001, Control wound treatment - Epidermolysis Bullosa | Phase 3 | Terminated | Shire Regenerative Medicine, Inc. | 1 | 2012-12-01 | 2013-11-21 |
| Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) Apligraf, Standard dressing regimen - Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica | Phase 3 | Terminated | Organogenesis | 1 | 2007-12-01 | 2010-06-29 |
Epidermolysis Bullosa (2) · Netherton Syndrome (2) · Capillary Malformations, Congenital, 1 (1) · Epidermolysis Bullosa Dystrophica (1) · Epidermolysis Bullosa, Junctional (1) · Port-Wine Stain (1)
Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Genetic Diseases, Inborn (5) · Skin Diseases, Genetic (5) · Skin Diseases, Vesiculobullous (3) · Abnormalities, Multiple (2) · Ichthyosiform Erythroderma, Congenital (2) · Ichthyosis (2) · Infant, Newborn, Diseases (2) · Keratosis (2) · Collagen Diseases (1) · Connective Tissue Diseases (1)
Brimonidine Tartrate (1) · Gels (1) · Injections (1) · spesolimab (1)
Boehringer Ingelheim (1) · Organogenesis (1) · Scioderm, Inc. (1) · Shire Regenerative Medicine, Inc. (1) · The Hospital for Sick Children (1) · University Hospital, Toulouse (1)
France (4) · United States (4) · Germany (3) · Australia (2) · Austria (2) · Canada (2) · Israel (2) · Netherlands (2) · Poland (2) · Portugal (2) · Spain (2) · United Kingdom (2) · Bulgaria (1) · China (1) · Italy (1)
Alan Arbuckle, MD, FAAD, FAAP (1) · Damien Bates, MD, PhD, FRACS (Plast.) (1) · Elena Pope, MD (1) · Elizabeth Alvarez- Connelly, MD (1)
2014 (1)